Investor Presentaiton

Oncology Opdivo Opdualag TIGIT Bispecific DGK Inhibitor AR LDD Confirmation of mechanism of action of AR LDD from first-in-human study 69 yr old male with mCRPC since 20221 Prior Tx: ADT, enzalutamide, avelumab + talazoparib Pt entered study with AR amplification, BRCA2 mutation, rising PSA and progressive soft tissue disease Treated with AR LDD; responded rapidly with PSA90* *Observed PSA decreases in this patient only serve to illustrate MoA and are not intended to represent expected outcomes Ill Bristol Myers Squibb™ 1. Patient case from BMS internal database ng/ml 1051028 PSA 70- 60- 50- 40- 30 20- 10- 8 12 16 Weeks 20 -30% -50% 24 28 -90% Not for Product Promotional Use 107

View entire presentation